Explosive advances in next-generation sequencer (NGS) and computational analyses have enabled exploration of somatic protein-altered mutations in most cancer types, with coding mutation data intensively accumulated. However, there is limited information on somatic mutations in non-coding regions, including introns, regulatory elements and non-coding RNA. Structural variants and pathogen in cancer genomes remain widely unexplored. Whole genome sequencing (WGS) approaches can be used to comprehensively explore all types of genomic alterations in cancer and help us to better understand the whole landscape of driver mutations and mutational signatures in cancer genomes and elucidate the functional or clinical implications of these unexplored genomic regions and mutational signatures. This review describes recently developed technical approaches for cancer WGS and the future direction of cancer WGS, and discusses its utility and limitations as an analysis platform and for mutation interpretation for cancer genomics and cancer precision medicine. Taking into account the diversity of cancer genomes and phenotypes, interpretation of abundant mutation information from WGS, especially non-coding and structure variants, requires the analysis of large-scale WGS data integrated with RNA-Seq, epigenomics, immuno-genomic and clinic-pathological information.
Genome Consortium (ICGC), 8 and hundreds of millions of cancer patients will have their genome sequenced by 2030. In these projects so far, WES is the main platform for cancer genome sequencing and vast amounts of mutational data in protein-coding regions have been accumulated for all types of common and rare human tumors.
These systematic studies of these cancer genome data have reveled scores of new cancer genes and pathways, 2 and saturation analysis suggests that most driver genes with frequent mutation in cancer have been almost elucidated. 9, 10 Researchers are now focusing on a "long tail" of rare mutated driver genes 2, 11 and rare variants of the driver genes, in addition to validating these functional or clinical implications by integrating with clinical data and using functional assays. Pan-cancer analysis on WES data demonstrated that carcinogen-exposed cancer, such as melanoma and lung cancer, have far higher numbers of somatic mutations in coding regions among common cancers, while pediatric tumors and leukemia have much fewer mutations and only several protein-altered mutations are present in their whole coding regions. 12, 13 TCGA and ICGC provide comprehensive mutational data of coding regions in more than 20 000 cancers and the COSMIC database 14 has been extensively curating mutations from targeted sequencing and WES, summarizing coding mutations for more than 1 000 000 cancer samples. However, there is limited information on somatic mutations in non-coding regions spanning 98% of the human genome, which includes untranslated regions (UTR), introns, promoters, regulatory elements, non-coding functional RNA, repetitive regions and mitochondrial genomes.
Somatic structural variants (SV) including large deletions/insertions, inversion, duplication, translocation and pathogen (virus) integration
in cancer genomes also remain widely unexplored ( Figure 1A ). WGS approaches can cover all of these unexplored mutations (Table 1) and help us to better understand the "whole" landscape of cancer genomes and elucidate the functions of these unexplored human genomic regions ( Figure 1A ). This approach combined with mathematical analysis and other omics analysis can clarify the underlying carcinogenesis and achieve molecular sub-classification of cancer, which facilitates discovery of genomic biomarkers and personalized cancer medicine. This review describes recent technical approaches for cancer WGS and the future direction of cancer WGS, and discusses its utility and limitations as an analysis platform and for mutation interpretation for cancer genomics and cancer precision medicine.
| NEXT-GEN ERATION SE QUENCER
TECHNOLOGY AND WHOLE GE NOME SEQUENCING AN ALYSIS which can cover 99% of the entire human genome. Common NGS technology reads are 100-150 bp for both ends of a 500-600-bp DNA fragment, 16 but WGS by NGS is still dependent on PCR, with PCR bias, indicating that GC-rich or AT-rich regions are difficult to sequence. PCR-free protocol was recently developed, which shows less GC bias and is more comprehensive than the PCR protocol, although some lg DNA is required as an input for library preparation. The largest limitation of the present 2nd NGS technology (Illumina SBS technology) 16 is its short-read length (100-250 bp).
Around 50% of the 3-Gb human genome is occupied by repetitive regions and pseudogenes in its 50%, and when short sequence reads are aligned to the redundant reference genome, alignment errors can occur around these repetitive or complicated regions, leading to mutation calling errors. 17 The 3rd generation NGS technologies such as PacBio SMART single molecule sequencing 18 and nanopore sequencing 19 can yield 10 kb and longer reads without PCR bias and are promising for analysis for human WGS; however, they currently suffer from a high error rate (5% and more) in each read and are still prohibitively expensive for WGS analysis, considering that the cost of human WGS was just below $1000 in 2017 (Table 1) .
| COMPUTATION AL ANALYSIS FOR
CANCER WHOLE GENOME SEQUENCING 
| MUTATIONS IN CODIN G REGIONS AND SPLICING SITES
Whole genome sequencing can detect somatic SNV and short indels
(1-10 bp) in coding regions and splicing sites near the exon-intron 
Promoter mutation ○

Regulatory regions ○
Copy-number alteration
Assay cost ($) 100 200-500 500 500 1000 SNV, single nucleotide variants; WGS, whole genome sequencing.
F I G U R E 2 A representative set of computational tools for cancer whole genome sequencing (WGS) analysis. As an initial step, raw sequence data (90-150-Gb 92: FASTQ files) from next-generation sequencer (NGS) of cancer genome and normal genome are aligned to the 3-Gb human reference sequence (3 Gb), producing BAM files. PCR duplication is removed from the BAM file (usually a few percent). Somatic mutations are called by several types of algorithms specific to mutation types (SNV, short indels, CNA, SV and others), comparing variant allele numbers in cancer genomes with those in normal genomes by statistical analysis and creating a list of somatic mutations (VCF files). Germline variant call including SNV and indels is commonly performed from sequencing data of normal genomes using other software Whole genome sequencing analysis in melanoma samples revealed hotspot mutations in the TERT promoter, located À124 bp and À146 bp upstream from the translation start ATG site and conferred enhanced TERT promoter activity. 37 These promoter mutations were frequently detected in glioblastoma, bladder cancer, thyroid cancer, liver cancer and melanoma, although the strength of association between these TERT promoter mutations and TERT expression is variable among cancer types. 38 In a subset of T-cell ALL, somatic mutations in non-coding regions introduced binding motifs for the MYB transcriptional factor and created a super-enhancer upstream of the TAL1 oncogene. 39 Recent systematic or statistical analysis for non-coding somatic mutations using WGS datasets from TCGA and ICGC indicated that several non-coding regions are frequently mutated, such as the promoters or regulatory elements of PLEKHS1, WDR74, TFPI2 and BCL6. 32, 40, 41 There are a lot of CTCF/ cohesion-binding sites (CBS) across the human genome, which function as insulators to regulate gene expression of nearby genes.
Multiple cancer types accumulate CBS mutations 42 and these mutations may be involved in the generation of double-strand breaks and SV as well. 43 To identify non-coding mutations and to interpret their impacts and consequences, more systematic approaches are required by integrating many datasets targeting non-coding regulatory regions, such as ENCODE, 34 FANTOM, 30 ChIP-Seq datasets (epigenomic data) and gene expression datasets (RNA-Seq).
| COPY NUMBER ALTERATIONS
Copy number alterations (CNA), affecting large DNA segments reads mapped to specific genomic regions in cancer/normal DNA.
Even low-depth WGS (90.1) can efficiently detect CNA in cancer genomes. 47 The theological base of non-invasive prenatal genetic testing (NIPT) is that CNA of a fetus are detected in plasma of pregnant women, 48 and this method of low-depth WGS is applied to cancer patients as a liquid biopsy or ctDNA (circulating tumor DNA)
analysis. Indeed, NIPT by WGS can detect CNA of cancer in lowdepth WGS of plasma from cancer-bearing pregnant women. 49 
| STRUCTURE VARIANTS
Distinct rearrangements or SV in leukemia and sarcoma lead to the activation of proto-oncogene products or creation of cancer-specific fusion genes, some of which are clinical diagnostic tools, such as STY-SSX1 fusion in synovial sarcoma and EWS-FLI1 fusion in Ewing sarcoma. 50 Philadelphia chromosome in CML, 51 translocation between chromosome 9q34 and 22q11 gives rise to the BCR-ABL fusion gene, to which the ABL kinase inhibitor imatinib for first time successful targeted in CML. A small inversion on 2p creates the EML4-ALK fusion gene, which is found in 1%-2% of lung adenocarcinomas, and kinase inhibitors are targeting such a kinase fusion gene as ALK in lung cancer. 52 SV involving ROS1 at 6q22 (mainly translocation) and RET1 at chromosome 10q11.2 (mainly inversion) were also identified in a small percentage of lung cancers with unique clinical and pathological features. They produce fusion kinases as driver genes and are molecular targets for lung cancer 53, 54 ; 40%-70% of prostate cancers were found to have SV involving ERG at 21q22 and multiple ETS family genes, producing TMPRSS2-ERG and ETS family gene fusions. 55 Recent analysis for medulloblastoma found recurrent SV activated GFIB proto-oncogene by enhancer hijacking. 56 In liver and kidney cancers, the promoter regions of TERT are frequently affected by SV, inducing TERT overexpression. 32 SV affects CD274 (PD-L1) genes in specific types of lymphoma, 57 inducing the stability of PD-L1 and associated with immune escape of cancer cell. 61 and Gammaproteobacteria in pancreatic cancer. 62 WGS of liver cancers detected several integration sites of the HBV DNA genome (3 kb), which preferentially integrated to the genomic regions of the TERT and MLL4 loci. 32, 63 The HPV DNA genome and its integrations are detected by WGS for cervical cancer 64 and head and neck cancer. Several rare cancers have a strong viral component, such as EBV in Burkitt lymphoma 65 and nasopharyngeal carcinoma, and RNA retrovirus HTLV-1 in adult T-cell leukemia/lymphoma. 66 Adeno-associated virus (AAV) is also reported to be integrated in liver cancer genome, 32 although its pathogenesis is unclear. These viral integrations/interactions are likely to lead to local genomic instability followed by copy number changes, overexpression around the integration sites, and human-human or human-virus gene fusion events, in addition to oncoproteins derived from viral genome.
| MUTATIONAL ANALYSIS IN REPEAT OR REPETITIVE REGIONS
| MUTATIONS IN MITOCHONDRIA GEN OME
Whole exome sequencing is not designed to capture the 16-kb mitochondria genome, which includes 13 protein-coding genes that are equipped with all the elements necessary for their own protein synthesis. 67 The proteins encoded by mitochondrial DNA (mtDNA) genes work with other nuclear genes to form the respiratory chain complexes that are the main energy production system in cells. The involvement of mitochondria in carcinogenesis has long been suspected and altered energy metabolism is a common feature of cancer. 68 Some studies have examined mtDNA copy numbers in individual cancer types 68 or from a collection of WES data 69 
| GENOMIC INSTABILITY AND CELL-OF-ORIGIN PRE DICTION BY MUTATIONAL SIGNATURE
Whole genome sequencing analysis of cancer revealed a distinct signature pattern, termed chromothripsis, 76 in which, 1 or a few chromosomes in 1 cell produce dozens to hundreds of clustered SV (Figure 1b) . The mechanism for such complicated SV is that at 
| CONCLUSION AND FUTURE
DIRECTION OF CANCER WHOLE GENOME SEQUENCING
As sequencing costs continue to decrease and computer resources expand, WGS analysis for cancer genome research and clinical utilities will become more common and more sophisticated. Cancer WGS provides abundant information to understand the biology underlying the cancer genome and the function of unexplored noncoding regions and SV in the human genome. There is much potential for transcriptional or functional consequences of SV and noncoding mutations and they should be further explored by integrative analysis of RNA-Seq and multi-omics analysis with DNA methylation data, 78 protein expression data, and chromatin structure 85 or epigenome data to interpret mutational consequences and to understand the biology and immunology of cancer. Taking into account the diversity of cancer genomes and phenotypes, interpretation of the mutational data from cancer WGS will also require the analysis of much more WGS data and integration with multi-omics data, functional data, immuno-genomic data and clinic-pathological data in a larger sample set.
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